within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02C_AntinematodalAgents.P02CA03_Albendazole;

model Albendazole
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.05,
    Cl = 8.166666666666666e-06,
    adminDuration = 600,
    adminMass = 400 / 1000000,
    adminCount = 1,
    Vd = 0.0008,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0025,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Albendazole</td></tr><tr><td>ATC code:</td><td>P02CA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>400</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.42</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Albendazole is an anthelmintic drug used to treat a broad range of parasitic worm infestations, including neurocysticercosis, hydatid disease, giardiasis, and soil-transmitted helminthiases. It disrupts the microtubule formation in parasites, leading to their immobilization and death. Albendazole is widely approved and used globally for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after a single 400 mg oral dose, under fasting conditions.</p><h4>References</h4><ol><li><p>Whittaker, C, et al., &amp; Boussinesq, M (2022). Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis. <i>PLoS neglected tropical diseases</i> 16(10) e0010497–None. DOI:<a href=\"https://doi.org/10.1371/journal.pntd.0010497\">10.1371/journal.pntd.0010497</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36306320/\">https://pubmed.ncbi.nlm.nih.gov/36306320</a></p></li><li><p>Fimbo, AM, et al., &amp; Aklillu, E (2023). Population pharmacokinetics of ivermectin after mass drug administration in lymphatic filariasis endemic communities of Tanzania. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 12(12) 1884–1896. DOI:<a href=\"https://doi.org/10.1002/psp4.13038\">10.1002/psp4.13038</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37638539/\">https://pubmed.ncbi.nlm.nih.gov/37638539</a></p></li><li><p>Pettarin, M, et al., &amp; Kostewicz, ES (2020). A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 155 105552–None. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2020.105552\">10.1016/j.ejps.2020.105552</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32937212/\">https://pubmed.ncbi.nlm.nih.gov/32937212</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P02CA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Albendazole;
